# Woori IO

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/woori-io
Canonical HTML page: https://getbiobrief.com/entity/woori-io

## Recent coverage (1 stories)

### Woori IO and Sinopharm Sign NDA for China Market and Global Clinical Trials
2026-03-19 18:39:16 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Woori IO, a subsidiary of OSR Company, has entered into a strategic Non-Disclosure Agreement (NDA) with Chinese pharmaceutical giant Sinopharm to explore commercialization opportunities in mainland China. The partnership also outlines a framework for collaboration on global multicenter clinical trials, signaling a major expansion for OSR's therapeutic pipeline into the world's second-largest pharmaceutical market.
Full story: https://getbiobrief.com/story/woori-io-sinopharm-china-market-partnership

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.